CHILDREN'S MEDICAL CENTER DNA/CELL/TISSUE REPOSITORY (CMCDR)

Study ID
STU 102010-052

Cancer Related
No

Healthy Volunteers
Yes

Study Sites

Contact
Emma Sanchez
214-456-7974
emma.sanchez@childrens.com

Principal Investigator
Linda Baker

Summary

To discover the genetic causes of undefined pediatric disorders, the Children's Medical Center (CMC) at Dallas Dna/Cell/Tissue Repository (CMCDR) will house the samples of affected children and their participating family members.

Patients with a possible genetic disorder that meet study eligibility criteria will be offered study participation. The informed consent and recruitment methods will depend upon whether they are local, national/international, or from an outside institution. Research information will be collected, including Dna/tissue samples, demographic data and clinical data, and will be housed in iRB-approved databases and storage facilities. information and samples will be withdrawn from this repository after specific iRB approved protocols have been written to study select subjects in this repository. The number of existing charts, records, or specimens will vary depending on the possible genetic disorder included in the repository.

This repository will be ongoing for at least 10 years with projected maximum recruitment of 3,000 subjects. Condition for study exit prior to completion may include: noncompliance, safety reasons, and subject withdrawal of consent.

Participant Eligibility

Patients of all ages, both sexes and all ethnic backgrounds will be included. The vast majority of patients will be in excellent overall health status with a possible genetic problem. However, a small minority of patients will be in poorer general health status due to the nature of their disease (for example, birth defects and genetic disorders). In cases where a positive family (history of disease) has been detected, the extended family of the proband will be invited to participate in the study and parents will be specifically invited for participation. Minor patients will be included in the study only if legal guardians are capable of providing informed consent. Patients/guardians able to speak and read English and Spanish (with translators) are eligible for enrollment.